


CLAIMS

1. A compound of formula (I), or an N-oxide or pharmaceutically acceptable salt thereof:




Formula (I)

wherein:


L1 is linker selected from a carbon-carbon triple bond or a carbon-carbon double bond;

L2 is a linker selected from -NHC(O)-, -C(O)NH-; and

A is selected from the group consisting of:




2. The compound according to claim 1 or an N-oxide or pharmaceutically acceptable salt thereof, which compound is a compound of formula (Ia):



Formula (Ia)

3. The compound according to claim 1 or an N-oxide or pharmaceutically acceptable salt thereof, which compound is a compound of formula (Ib):




Formula (Ib)

4. The compound according to claim 1 or an N-oxide or pharmaceutically acceptable salt thereof, which compound is selected from the group consisting of:

- a. 4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(7-oxo-8H-1,8-naphthyridin-3-yl)ethynyl]benzamide;
- b. 4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[(E)-2-(7-oxo-8H-1,8-naphthyridin-3-yl)vinyl]benzamide;
- c. N-[4-methyl-3-[2-(7-oxo-8H-1,8-naphthyridin-3-yl)ethynyl]phenyl]-4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)benzamide;
- d. 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[2-(7-oxo-8H-1,8-naphthyridin-3-yl)ethynyl]benzamide;
- e. 4-methyl-N-[3-[(4-methylpiperazin-1-yl)methyl]-5-(trifluoromethyl)phenyl]-3-[2-(7-oxo-8H-1,8-naphthyridin-3-yl)ethynyl]benzamide;
- f. N-[3,5-bis(trifluoromethyl)phenyl]-4-methyl-3-[2-(7-oxo-8H-1,8-naphthyridin-3-yl)ethynyl]benzamide;
- g. N-[4-methyl-3-[2-(7-oxo-8H-1,8-naphthyridin-3-yl)ethynyl]phenyl]-3,5-bis(trifluoromethyl)benzamide;
- h. 4-methyl-3-[2-(7-oxo-8H-1,8-naphthyridin-3-yl)ethynyl]-N-[3-(trifluoromethyl)phenyl]benzamide; and
- i. N-[4-methyl-3-[2-(7-oxo-8H-1,8-naphthyridin-3-yl)ethynyl]phenyl]-3-(trifluoromethyl)benzamide.


5. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, which compound is 4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(7-oxo-8H-1,8-naphthyridin-3-yl)ethynyl]benzamide.

6. A process for the synthesis of a compound of the formula (I)




Formula (I)

or N-oxide or pharmaceutically acceptable salts thereof, which process comprises reacting a compound of formula (IIa) or formula (IIb)




Formula (IIa)



Formula (IIb)

with a compound of formula III:




Formula (III)

wherein:

L1 is linker selected from a carbon-carbon triple bond or a carbon-carbon double bond;

L2 is a linker selected from -NHC(O)-, -C(O)NH-; and

A is selected from the group consisting of:



7. A process according to claim 6 for the synthesis of 4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(7-oxo-8H-1,8-naphthyridin-3-

yl)ethynyl]benzamide or a pharmaceutically acceptable salt thereof, which process comprises reacting 3-halo-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide with 6-ethynyl-1H-1,8-naphthyridin-2-one in presence of a suitable catalyst and solvent.

8. A process according to claim 7, wherein the process further comprises converting 4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(7-oxo-8H-1,8-naphthyridin-3-yl)ethynyl]benzamide into a pharmaceutically acceptable salt.

9. A pharmaceutical composition comprising (i) a compound as defined in any one of claims 1 to 5, or an N-oxide or pharmaceutically acceptable salt thereof and (ii) a pharmaceutically acceptable carrier.

10. A pharmaceutical composition according to claim 9, which pharmaceutical composition comprises (i) 4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(7-oxo-8H-1,8-naphthyridin-3-yl)ethynyl]benzamide or a pharmaceutically acceptable salt thereof and (ii) a pharmaceutically acceptable carrier.

11. Use of a compound as defined in any one of claims 1 to 5 or an N-oxide or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a proliferative disorder.

12. The use according to claim 11, wherein the compound is 4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(7-oxo-8H-1,8-naphthyridin-3-yl)ethynyl]benzamide or a pharmaceutically acceptable salt thereof.

13. The use according to claim 11 or claim 12, wherein the proliferative disorders is selected from the group consisting of leukemia, chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), myelodysplastic syndrome, melanoma, germ cell tumours, gastrointestinal stromal tumour (GIST), non-small cell lung cancer (NSCLC), mastocytosis, neuroblastoma, glioblastoma, astrocytoma, hepatocellular carcinoma, renal cell cancer, breast cancer, cutaneous systemic sclerosis, prostate cancer, colorectal cancer and diabetes remissions.